Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBest
Authors:
- Brigitte StephanBSBrigitte Stephan
- Stephan Jeff RustenbachSRStephan Jeff Rustenbach
- Nesrine Ben-AnayaNBNesrine Ben-Anaya
- Matthias AugustinMAMatthias Augustin
- Wolf-Henning BoehnckeWBWolf-Henning Boehncke
- Michael HertlMHMichael Hertl
- Ulrich MrowietzUMUlrich Mrowietz
- Petra Staubach-RenzPSPetra Staubach-Renz
- Diamant ThaçiDTDiamant Thaçi
- Ralph von KiedrowskiRKRalph von Kiedrowski
- Christina SorbeCSChristina Sorbe
Open Access
- 26 June 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (13) , 3713
Abstract
Background: Patients with psoriasis under systemic treatments are in focus regarding their susceptibility to respiratory infections. To analyse real-world data for respiratory infections in patients with psoriasis under systemic treatments. Methods: We analysed data of the prospective, non-interventional German Psoriasis Registry PsoBest and compared rates for respiratory infections of 13,823 patients on systemic treatments for psoriasis and/or psoriatic arthritis in different therapy cohorts before the COVID-19 pandemic. Results: In total, 1415 respiratory infections were observed in 970 patients. Significant differences were observed between biologics and non-biologics, but not within these groups. The highest event rates (events/100 patient years) were identified for TNF-α inhibitors, 8.1, (CI 7.4–8.9), followed by 7.0 for IL-17 inhibitors (6.2–7.9), 5.7 for IL-12/23 and IL-23 inhibitors (5.1–6.5), 4.8 for methotrexate (4.3–5.4), 3.7 for small molecules (3.3–4.2), and 2.7 for retinoids (1.2–5.1). Conclusions: Overall, the susceptibility for respiratory infections in patients under systemic therapy for psoriasis is low compared to published study data and is sufficient as comparative data for COVID-19 studies.Keywords
Funding Information
- AbbVie
- Almirall
- Amgen
- Biogen
- BMS
- Celgene
- Hexal
- Janssen-Cilag
- LEO Pharma
- Eli Lilly
- Medac
- Novartis
- Pfizer
- UCB
- Viatris
This publication has 62 references indexed in Scilit:
- Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic ArthritisArthritis & Rheumatology, 2022
- Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 TrialsRheumatology and Therapy, 2021
- Corona-Impfstoffe geeignet bei immunmodulierender TherapieDer Deutsche Dermatologe, 2021
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, ChinaJAMA Internal Medicine, 2020
- Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the LiteratureDermatology and Therapy, 2020
- Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT)Archives of Dermatological Research, 2019
- Impfen bei ImmundefizienzBundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2019
- Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBestArchives of Dermatological Research, 2015
- Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: Results of a multicenter studyJournal of the American Academy of Dermatology, 1995
- Methotrexate for PsoriasisArchives of Dermatology, 1971